SYNERGY PHARMACEUTICALS, INC. SGYP Cash Flow

Synergy pharmaceuticals, inc. (SGYP)

CashFlow / Quarterly

Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Mar'11
Cash Flows From Operating Activities:
Net loss
-34,543	-29,691	-36,104	-36,974	-48,871	-73,889	-64,604	-59,867	-40,243	-38,556	-59,941	-30,447	-25,996	-33,668	-27,389	-30,555	-23,008	-25,920	-16,225	-19,851	-13,537	-10,039	-18,697	-3,702
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
73	58	48	44	41	39	41	40	114	41	38	60	36	33	34	34	29	29	28	-	-	-	-	0
Amortization of deferred debt costs and debt discount
417	416	389	328	229	177	608	2,263	252	253	4,153	506	1,544	1,899	617	-	-	-	-	-	-	-	-	-
Accretion of back-end facility fee
-218	-188	-142	21	-21	0	0	-	-	-	-	12	10	74	13	-102	0	-4	-24	-14	53	-61	-37	-
Stock-based compensation expense
2,984	3,235	2,959	2,633	3,887	13,298	2,897	4,081	4,585	2,707	1,202	2,000	-70	5,389	2,405	1,535	923	1,000	1,264	1,356	1,090	911	1,257	147
Interest expense Payment-in-kind (PIK)
953	935	2,451	2,447	765	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of derivative financial instrumentswarrants
-433	2,604	5,644	4,124	55	39	122	-45	-86	-23	260	-30	1,446	-1,542	-268	-42	425	756	223	-484	-77	1,803	-1,093	-338
Common stock issued for interest on Notes
-	-	-	-	-	-	-	0	0	0	2,445	0	0	0	0	-	-	-	-	-	-	-	-	-
Debt conversion expense
0	0	0	0	0	0	1,209	14,543	0	0	25,615	0	0	0	0	-	-	-	-	-	-	-	-	-
Transaction fees on Note conversions
-	-	-	-	-	-	-	-	-	-1	435	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
711	1,097	923	1,455	3,254	-4,537	6,319	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventories
3,921	1,434	-1,039	-	1,192	2,206	4,007	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenues, net
-	0	5,000	-	-	-2,762	4,260	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest expense on short term notes borrowing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11
Security deposits
0	0	0	6	89	1	-65	0	0	0	0	-124	0	0	-56	-	-	-	-	-	-	-	-	-
Distribution of non-cash item - ContraVir net assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	84	-	-	-	-	-
Accounts payable and accrued expenses
4,409	-8,545	-1,004	6,524	-11,569	4,202	9,512	8,094	-1,094	5,346	-800	2,909	252	1,658	-2,952	-2,770	665	5,432	-3,011	2,509	5,198	-1,323	700	-64
Prepaid expenses and other current assets
-2,513	-1,152	4,455	-4,091	192	330	7,149	-855	-2,522	905	56	2,250	-1,232	-1,362	-187	-270	-692	-774	1,860	-1,526	2,895	775	27	-263
Accrued interest expense on senior convertible notes
348	-348	348	-348	348	-348	287	-2,180	1,484	-1,485	487	-2,982	2,747	-4,027	3,750	-	-	-	-	-	-	-	-	-
Total Adjustments
18,952	-8,044	350	4,137	-10,409	16,569	1,152	22,101	8,383	5,981	32,389	133	4,356	7,782	4,240	2,124	1,884	6,330	-3,694	5,917	3,445	-2,929	3,060	698
Net Cash used in Operating Activities
-15,591	-37,735	-35,754	-32,837	-59,280	-57,320	-63,452	-37,766	-31,860	-32,575	-27,552	-	-	-	-	-	-	-	-	-	-	-	-15,637	-3,003
Net Cash used in Operating Activities
-	-	-	-	-	-	-	-	-	-	-	-	-21,640	-25,886	-23,149	-	-21,124	-19,590	-19,919	-	-	-	-	-
Cash Flows From Investing Activities:
Loans to related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	270	-
Net sales (purchases) of available-for-sale securities
-	-	-	-	-	-	-	0	0	0	-50,097	-49,988	188	0	50,000	-	-	-	-	-20,000	-14,000	72,000	-8,000	-
(Loans to) /Repayment from related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	120
Additions to property and equipment
0	89	104	162	33	0	15	0	25	229	43	0	42	0	8	69	47	29	28	0	156	381	78	-
Repayment on ContraVir loan receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	455	-	-	-	-	-
Net Cash used in Investing Activities
0	-89	-104	-162	-33	0	-15	0	-25	-229	50,054	-	-	-	-	-	-	-	-	-	-	-	7,652	120
Net Cash provided by (used in) Investing Activities
-	-	-	-	-	-	-	-	-	-	-	-	-230	0	-50,008	-	29,953	-29	427	-	-	-	-	-
Cash Flows From Financing Activities:
Proceeds of sale of common stock, net of issuance costs
0	0	0	52,198	0	0	121,604	0	0	89,845	0	-404	0	9,114	5,558	5,088	2,817	189	22,606	0	0	90,063	4,671	-
Proceeds of sale of common stock ContraVir
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	3,224	-	-	-	-	-
Fees and expenses note conversions
-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-	-
Payment for deferred financing costs
0	0	2,500	0	0	0	1,591	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Fees and expenses sale of common stock
-	-	-	-	-	-	-	-	0	0	0	-	0	251	153	140	77	5	639	0	0	5,483	140	185
Proceeds from sale of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,800
Proceeds from exercise of stock options
5	399	30	0	0	18	329	9	190	23	0	-	-	-	-	0	0	0	36	0	0	14	105	-
Distribution associated with ContraVir Spinoff
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	3,230	-	-	-	-	-
Proceeds from issuance of short term note
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	500
Net Cash (used in) provided by Financing Activities
5	399	-2,470	52,198	95,140	18	120,342	11,063	-244	89,868	0	-	-	-	-	-	-	-	-	-	-	-	4,636	2,115
Net increase (decrease) in cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,349	-768
Net Cash provided by Financing Activities
-	-	-	-	-	-	-	-	-	-	-	-	2,091	8,863	5,405	-	2,740	184	21,997	-	-	-	-	-
Net decrease in cash and cash equivalents
-15,586	-37,425	-38,328	-	35,827	-57,302	56,875	-	-32,129	57,064	22,502	-	-19,779	-17,023	-67,752	-	11,569	-19,435	2,505	-	-	-	-	-
Supplementary disclosure of cash flow information:
Cash paid for taxes
1,133	0	0	0	-24	0	44	0	0	0	45	0	34	102	122	0	25	0	30	44	10	9	18	5
Supplementary disclosure of non-cash investing and financing activities:
Recapitalization of Synergy
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-4,904	-
Distribution of net assets of ContraVir
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	84	-	-	-	-	-
Conversion of senior convertible notes to Synergy Common Stock
0	0	0	0	0	0	4,912	55,667	0	0	82,274	0	18,776	22,213	0	-	-	-	-	-	-	-	-	-
Fair value of warrants classified to derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,312